Novel transcript, antisense to BCL6 corepressor

This target, "novel transcript, antisense to BCOR" (ENSG00000303020), refers to a long non-coding RNA (lncRNA) transcribed in the antisense direction at the BCOR locus. Antisense transcripts such as this are widespread throughout the genome and can regulate the expression of their sense (protein-coding) partners through mechanisms including modulation of chromatin structure, transcriptional interference, and RNA stability[1][3][5]. These antisense RNAs often function in *cis*, affecting the adjacent coding gene, and have been implicated in fine-tuning gene expression as well as establishing proper chromatin environments[1][3][5]. There is no evidence that this particular antisense transcript encodes a protein or serves as a standalone therapeutic target; instead, it may modulate the expression of the adjacent BCOR gene, which is critical in development and hematologic diseases[4][6]. This entry is not a canonical therapeutic target such as a receptor, enzyme, or channel, and annotation as a therapeutic target would be considered incorrect. Key clarifications: - The entry does not correspond to a protein or known druggable receptor, enzyme, etc., but rather to a lncRNA whose precise functional role, if any, is likely regulatory and not currently defined as a disease biomarker or drug target[1][3][5]. - There is no evidence of interacting drugs, therapeutic mechanism of action, biomarkers, or major safety concerns for this antisense transcript itself. Summary of why this is not a conventional target: The designation is likely used in transcriptomics to flag non-coding, regulatory transcripts, but it should not be considered a classic drug discovery or therapeutic target[1][5]. If your application requires protein targets or actionable biological entities, this entry is not appropriate.

Other names

antisense to BCORantisense non-coding RNA at BCOR